Atossa Therapeutics is advancing (Z)-endoxifen as a potential treatment for McCune-Albright syndrome, extending the drug’s reach into rare endocrine disorders w

Atossa Therapeutics is advancing (Z)-endoxifen as a potential treatment for McCune-Albright syndrome, extending the drug’s reach into rare endocrine disorders with high unmet need. The move builds on prior breast cancer progress and broadens its pipeline strategy.